

Adopted at the Annual General Meeting on: June 7, 2024

---

Mikkel Viltoft  
*Chairman*

## **Novozymes Biopharma DK A/S**

Krogshøjvej 36, 2880 Bagsværd

CVR No 29 60 35 37

## **ANNUAL REPORT 2023**

## **Management's Statement**

The Executive Board and the Board of Directors have today considered and adopted the Annual Report of Novozymes Biopharma DK A/S for the financial year 1 January - 31 December 2023.

The Annual Report is prepared in accordance with the Danish Financial Statements Act. We consider the accounting policies applied appropriate and the estimates made reasonable.

In our opinion, the Financial Statements give a true and fair view of the financial position at 31 December 2023 of the Company and of the results of the Company operations for 2023.

In our opinion, Management's Review includes a true and fair account of the matters mentioned and describes the most significant risks and elements of uncertainty facing the Company.

We recommend that the Annual Report be adopted at the Annual Shareholders' Meeting.

Bagsværd, June 7, 2024

### **Executive Board**

Mikkel Viltoft

### **Board of Directors**

Camilla Kinch Jensen  
*(Chair)*

Rainer Lehmann

Mikkel Viltoft

## **Independent Auditor's Report**

To the Shareholders of Novozymes Biopharma DK A/S

### **Opinion**

In our opinion, the Financial Statements give a true and fair view of the financial position of the Company at 31 December 2023, and of the results of the Company's operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.

We have audited the Financial Statements of Novozymes Biopharma DK A/S for the financial year 1 January - 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies ("financial statements").

### **Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Statement on Management's Review**

Management is responsible for Management's Review.

Our opinion on the financial statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, in our view, Management's Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement in Management's Review.

### **Management's Responsibilities for the Financial Statements**

Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

## **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Hellerup, June 7, 2024

### **PricewaterhouseCoopers**

Statsautoriseret Revisionspartnerselskab

*CVR No 33 77 12 31*

Christian Møller Gyrsting  
State Authorised Public Accountant  
mne44111

Martin Jarness Schmidt Andersen  
State Authorised Public Accountant  
mne49061

## **Management Review**

The purpose of the company is to operate and invest in research and development, production and trade with biological solutions, herunder biotechnological products and processes, as well as any business related to this as determined by the Board of Directors. The company strives to operate on a sustainable and responsible way, both financially, socially and environmentally.

For the financial year 2023 the company has realized a profit of DKK 14,907,714 which is line with expectations, when taking into account the effect of financial income.

The company proposes to pay ordinary dividend for the financial year of DKK 60,000,000.

### **Expectations for 2024**

Due to the sale of the last remaining royalty agreement in 2019, it is not expected that there will be activity in Novozymes Biopharma DK A/S going forward except for activities related to the sale of the royalties.

## Accounting policies

The Annual Report has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to small enterprises of reporting class B, with some voluntary additions from class C.

Accounting policies are unchanged compared to last year.

### Recognition and measurement

The Company's income and expenses are included in the Annual Report in consideration of full accrual of income and expenses.

Assets and liabilities are initially measured at cost. Subsequently, assets and liabilities are measured as described below

### Translation policies

Transactions in foreign currencies are translated into DKK at the exchange rates at the dates of transaction. Monetary items in foreign currencies are translated into DKK at the exchange rates at the balance sheet date. Realised as well as unrealised exchange gains and losses are recognised in financial income and expenses in the income statement.

### Other operating income

Other operating income includes items of a secondary nature, eg. contingent consideration.

### Other external expenses

Other external expenses include costs for administration, audit etc.

### Financial income and expenses

Financial income and expenses include interest, as well as gains and losses on financial assets, liabilities and transactions in foreign currency.

### Tax

Tax on profit for the year which comprises current tax for the year, change in deferred tax as well as any adjustments of previous years is recognised in the income statement. Deferred tax is measured under the balance sheet liability method and comprises all temporary differences between the carrying amount and the tax base of assets and liabilities. Deferred tax on goodwill is not recognized unless amortisations on goodwill are tax deductible.

Deferred tax is measured on the basis of applicable tax rules and at the tax rate expected to be effective when the temporary differences are eliminated. Any changes in deferred tax due to changes to the tax rates are recognised in the income statement.

The Company is jointly taxed with the Danish enterprises in the Novo Holdings A/S Group.

The tax of the individual enterprises is fully allocated on the basis of the expected taxable income

### Other investments

Other investments are recognised at the cost of the shares. Impairment losses on the investments are recognised, however, where the impairment is considered to be of a permanent nature.

### Receivables

Receivables are measured in the balance sheet at the lower of amortised cost and net realisable value which normally corresponds to nominal value less any loss allowance for bad debts. Loss allowance for bad debts are determined on the basis of an individual assessment of each receivable.

### Financial liabilities

Financial liabilities are measured at amortised cost, substantially corresponding to nominal value.

Financial liabilities include trade payables and payables to group enterprises.

## Income statement 1. January - 31. December 2023

	Note	<u>2023</u>	<u>2022</u>
		DKK	DKK
Other operating income	1	977,415	(242,698)
Other external expenses	2	<u>(65,652)</u>	<u>(156,497)</u>
<b>Gross profit</b>		<b><u>911,763</u></b>	<b><u>(399,195)</u></b>
<b>Operating profit</b>		<b><u>911,763</u></b>	<b><u>(399,195)</u></b>
Financial income	3	18,513,260	2,159,755
Financial expenses	4	(312,569)	(3,453,639)
Income/expenses from other investments	6	<u>-</u>	<u>267,421,221</u>
<b>Profit before tax</b>		<b><u>19,112,454</u></b>	<b><u>265,728,142</u></b>
Tax on profit for the year	5	<u>(4,204,740)</u>	<u>338,159</u>
<b>Net profit for the year</b>		<b><u>14,907,714</u></b>	<b><u>266,066,301</u></b>
<b>Distribution of profit</b>			
<b>Proposed distribution of profit</b>			
Proposed dividend		60,000,000	265,000,000
Transferred to retained earnings		<u>(45,092,286)</u>	<u>1,066,301</u>
		<b><u>14,907,714</u></b>	<b><u>266,066,301</u></b>

## Balance sheet at December 31, 2023

	Note	<b>2023</b>	<b>2022</b>
		DKK	DKK
<b>Assets</b>			
Other investments	6	-	-
<b>Financial fixed assets</b>		<b>-</b>	<b>-</b>
Receivables from group enterprises		75,316,730	321,861,972
Corporation tax receivable		-	418,824
Deferred tax assets	7	53,406	214,778
Other receivables		42,153	-
<b>Receivables</b>		<b>75,412,289</b>	<b>322,495,574</b>
<b>Cash at bank and in hand</b>		<b>507,498</b>	<b>500,512</b>
<b>Current assets</b>		<b>75,919,787</b>	<b>322,996,086</b>
<b>Assets</b>		<b>75,919,787</b>	<b>322,996,086</b>
<b>Liabilities and equity</b>			
Share capital	8	612,000	612,000
Retained earnings		10,835,180	55,927,466
Proposed dividend		60,000,000	265,000,000
<b>Equity</b>		<b>71,447,180</b>	<b>321,539,466</b>
Trade payables		77,500	-
Payables to group enterprises		133,138	121,883
Corporation tax		4,043,368	-
Other payables		218,601	1,334,737
<b>Short-term liabilities</b>		<b>4,472,607</b>	<b>1,456,620</b>
<b>Liabilities and equity</b>		<b>75,919,787</b>	<b>322,996,086</b>
Related parties	9		
Contingent liabilities	10		
Events after the reporting date	11		

## Statement of changes in equity

Share capital as of December 31, 2023 is specified as follows:

DKK	Share capital	Retained earnings	Proposed dividend	Total
Equity at January 1	612,000	55,927,466	265,000,000	321,539,466
Net profit for the year	-	14,907,714	-	14,907,714
Paid dividend	-	-	(265,000,000)	(265,000,000)
Proposed dividend	-	(60,000,000)	60,000,000	-
<b>Equity at December 31</b>	<b>612,000</b>	<b>10,835,180</b>	<b>60,000,000</b>	<b>71,447,180</b>

## Notes to the Annual Report

### 1 Other operating income

Other operating income in 2023 is related to sale of royalty agreements in previous years.

### 2 Employee costs

Remuneration to the Executive Board was incurred by the Parent Company Novozymes A/S, and no disclosure was made of the remuneration to the Executive Board with reference to section 98B(3) of the Danish Financial Statements Act.

### 3 Financial income

	<u>2023</u>	<u>2022</u>
	DKK	DKK
Interest income	24,315	7,736
Foreign exchange gain	11,203,317	-
Interest on receivables from group enterprises	7,285,628	2,152,019
	<u><b>18,513,260</b></u>	<u><b>2,159,755</b></u>

### 4 Financial expenses

Bank charges	(6,214)	(4,789)
Interest expenses	-	(11,793)
Foreign exchange loss	(59)	(3,437,057)
Interest on payables to group enterprises	(306,296)	-
	<u><b>(312,569)</b></u>	<u><b>(3,453,639)</b></u>

### 5 Tax on profit for the year

Tax on profit for the year	(4,043,368)	418,824
Deferred tax	(161,372)	(46,361)
Adjustment of deferred tax, previous year	-	(34,304)
	<u><b>(4,204,740)</b></u>	<u><b>338,159</b></u>

## Notes to the Annual Report

### 6 Other investments

	<u>2023</u>	<u>2022</u>
	DKK	DKK
Cost at 1. January	-	175,805
Disposals for the year	-	(175,805)
<b>Cost at 31 December</b>	<b>-</b>	<b>-</b>
<b>Carrying amount 31 December</b>	<b>0</b>	<b>0</b>

In 2022, other investments were disposed with a gain of DKK 267,421,221.

### 7 Deferred tax

Deferred tax assets 1 January	214,778	295,443
Adjustment, previous years	-	(34,304)
Adjustment for the year	(161,372)	(46,361)
<b>Deferred tax assets 31 December</b>	<b>53,406</b>	<b>214,778</b>

Deferred tax assets consist of:

Tangible assets	5,312	7,083
Transaction costs, net	48,094	207,695
<b>Deferred tax 31 December</b>	<b>53,406</b>	<b>214,778</b>

### 8 Share capital

Share capital amounts to DKK 612,000 and consists of 612,000 shares of DKK 1.

## Notes to the Annual Report

### 9 Related parties

Novozymes Biopharma DK A/S is a wholly-owned subsidiary of Novozymes A/S, Gladsaxe, and is included in the Consolidated of Statements of Novozymes A/S. The ultimate parent company preparing consolidated financial statements is the Novo Nordisk Foundation, Gentofte.

The Novo Nordisk Foundation and its subsidiaries, i.e. the Novo Group and the Novo Nordisk Group, members of the executive boards of these entities and the management of Novozymes A/S as well as their close family members are considered related parties. Related parties moreover comprise enterprises in which the above-mentioned group of people hold considerable interests.

### 10 Contingent liabilities

The company is jointly taxed with the Danish companies of the Novo Holdings A/S Group, and is individually liable for the joint taxation liability.

### 11 Events after the reporting date

No events have occurred after the reporting date of importance to the financial statements.